Compare National Beverage Corp. (FIZZ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Pfizer Inc — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.77B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 57.6× National Beverage Corp.'s market cap, and Pfizer Inc pays a 6.14% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Pfizer Inc for 158 Days on average.
| FIZZ | PFE | |
|---|---|---|
Market Cap | $2.77B | $159.59B |
Volume | 413,496 | 30,937,010 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $29.02 |
52-Week Low | $29.20 | $23.67 |
Typical Hold Time | 33 Days | 158 Days |
Enterprise Value | $2.72B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals from moving averages. The company reported flat revenue of $1.2B in 2025 but maintained strong profitability with 36.2% gross margins and 40.1% ROE. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026, though margins compressed to 35% and EPS declined to $0.50. Analyst sentiment is cautious with 50% sell ratings amid concerns about stalled growth and margin pressure from input costs.
The outlook remains challenging with LaCroix volumes declining for four consecutive years and Trump tariffs impacting profitability. While valuation multiples appear reasonable (P/E 15.9, EV/EBITDA 11.3), the lack of clear growth catalysts and negative cash flow trends present headwinds. The $3.25 special dividend provides shareholder return but reduces equity base, highlighting the company's mature market position.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
